Bern, Monday 12 September 2016 10.00 GMT
After nearly four years of research and development, we are proud to announce that velibra, our digital therapy software for anxiety disorders, has demonstrated efficacy in a high quality randomized controlled trial. The trial’s Principal Investigator, Prof. Thomas Berger, concluded in Psychological Medicine, the journal in which results were recently published, that velibra “is effective in reducing symptomatology and in increasing psychological well-being assessed as early as 9 weeks after treatment initiation.” We thank our partners and patients who supported us on this successful research and development journey.
You can refuse the use of Google Analytics by clicking on the following link. An opt-out cookie will be set on the computer, which prevents the future collection of your data when visiting this website: Disable Google Analytics
Further information concerning the terms and conditions of use and data privacy can be found at http://www.google.com/analytics/terms/gb.html or at http://www.google.com/intl/en/analytics/privacyoverview.html.
Please note that on this website, Google Analytics code is supplemented by “gat._anonymizeIp();” to ensure an anonymized collection of IP addresses (so called IP-masking).